Overview
With $400 million in assets under management, H.I.G. BioHealth Partners invests in a broad range of healthcare companies across multiple sectors and stages of development. Our seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. We invest in companies developing novel products for significant unmet medical needs more >
Portfolio
Recent News
- Wed, Apr 3rd, 2019 — Clarus Therapeutics Receives U.S. FDA Approval of JATENZO® (Testosterone Undecanoate Capsules…
- Tue, Mar 26th, 2019 — Apollo Endosurgery Appoints John Barr to Board of Directors
- Tue, Mar 26th, 2019 — On Target Laboratories Appoints Executive Vice President of Regulatory and Quality
- Mon, Mar 25th, 2019 — CardioFocus Announces European CE Mark Approval of Breakthrough HeartLight® X3 System for…
- Tue, Mar 5th, 2019 — CardioFocus Initiates Persistent Atrial Fibrillation Study with the Breakthrough HeartLight®…
- Thu, Feb 14th, 2019 — SK Biopharmaceuticals and Arvelle Therapeutics Announce Agreement to Develop and Commercialize…
- Tue, Feb 12th, 2019 — On Target Laboratories Announces Amendment to Ongoing Phase 3 Trial Expanding Camera System…
- Thu, Feb 7th, 2019 — H.I.G. Capital Completes Acquisition of Taconic Biosciences
- Mon, Feb 4th, 2019 — Neurana Pharmaceuticals Announces First Patient Enrolled in the STAR Study
- Tue, Jan 15th, 2019 — On Target Laboratories Appoints Vice President of Marketing and Commercialization